Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Return on Capital Employed (2021 - 2025)

Vivos Therapeutics has reported Return on Capital Employed over the past 5 years, most recently at 271.77% for Q4 2025.

  • Quarterly Return on Capital Employed fell 16370.0% to 271.77% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 271.77% through Dec 2025, down 16370.0% year-over-year, with the annual reading at 928.76% for FY2025, 78963.0% down from the prior year.
  • Return on Capital Employed was 271.77% for Q4 2025 at Vivos Therapeutics, down from 88.7% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 14.27% in Q4 2021 and troughed at 534.7% in Q4 2023.
  • The 5-year median for Return on Capital Employed is 117.88% (2025), against an average of 185.07%.
  • Year-over-year, Return on Capital Employed tumbled -32831bps in 2023 and then surged 42663bps in 2024.
  • A 5-year view of Return on Capital Employed shows it stood at 14.27% in 2021, then plummeted by -1800bps to 271.15% in 2022, then plummeted by -97bps to 534.7% in 2023, then surged by 80bps to 108.07% in 2024, then plummeted by -151bps to 271.77% in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Return on Capital Employed are 271.77% (Q4 2025), 88.7% (Q3 2025), and 116.37% (Q2 2025).